Trial Profile
CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer's Disease [EXTENSION OF 700030204]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms CONNECTION-PLUS
- 01 Apr 2022 This trial has been completed in France (End Date: 6 Oct 2010) according to European Clinical Trials Database record.
- 05 Mar 2013 New trial record